Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study

Diabetes, Obesity & Metabolism
J J FeinerMarie Gelato

Abstract

Multidrug regimens in HIV disease are associated with an increased incidence of insulin resistance, by as much as 50%. Not only does insulin resistance predisposes subjects to diabetes but also it is associated with the metabolic syndrome and increased risk of cardiovascular disease. Previous studies suggest that chromium picolinate can improve insulin resistance in patients with type 2 diabetes. The objective was to study the efficacy and safety of chromium picolinate as a treatment of insulin resistance in subjects infected with HIV. The ability of chromium picolinate (1000 mug/day) to improve insulin sensitivity, determined with a hyperinsulinaemic-euglycaemic insulin clamp, was determined in eight HIV-positive subjects on highly active antiretroviral therapy. The mean rate of glucose disposal during the clamp was 4.41 mg glucose/kg lean body mass (LBM)/min (range 2.67-5.50), which increased to 6.51 mg/kg LBM/min (range 3.19-12.78, p = .03), an increase of 25% after 8 weeks of treatment with chromium picolinate. There were no significant changes in blood parameters, HIV viral burden or CD4+ lymphocytes with chromium picolinate treatment. Two subjects experienced abnormalities of liver function during the study. Another subje...Continue Reading

References

Oct 1, 1989·The Science of the Total Environment·C M WitmerS I Shupack
Mar 1, 1985·Metabolism: Clinical and Experimental·J F PotterD Elahi
Nov 1, 1971·The American Journal of Clinical Nutrition·C T Gürson, G Saner
Feb 1, 1968·Metabolism: Clinical and Experimental·R A LevineR J Doisy
Mar 1, 1968·The American Journal of Clinical Nutrition·L L HopkinsA S Majaj
Sep 1, 1983·Metabolism: Clinical and Experimental·R A AndersonW Glinsmann
Apr 11, 1996·The New England Journal of Medicine·J P DesprésP J Lupien
Mar 1, 1997·Annals of Internal Medicine·W G WasserV D D'Agati
Aug 1, 1997·The American Journal of Medicine·S M Haffner, H Miettinen
Apr 30, 1998·The Annals of Pharmacotherapy·J CerulliM D McGoldrick
Dec 16, 1998·Journal of the American College of Nutrition·R A Anderson
Jun 3, 1999·Endocrinology and Metabolism Clinics of North America·L L Amowitz, B E Sobel
Jul 25, 2000·JAMA : the Journal of the American Medical Association·C HadiganS Grinspoon
Oct 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·B W MorrisS Heller
Dec 11, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Dennis C MynarcikMarie C Gelato
Mar 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Dion D D HepburnJanis O'Donnell
Nov 25, 2003·The New England Journal of Medicine·Nina Friis-MøllerUNKNOWN Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
Oct 27, 2004·Diabetes Care·William T Cefalu, Frank B Hu
Oct 12, 2005·Mutation Research·Ramadevi GudiRichard H C San

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
M HummelO Schnell
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Ather AliDavid L Katz
© 2021 Meta ULC. All rights reserved